RxDoctor Payments Data

Dmitriy Timerman

Dermatology · Danbury, CTNPI 1174986525

Payments from drug & device makers

$6,617in general payments, 2019–2025

Across 328 payments — averaging $20.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Johnson & Johnson$848
  • LEO Pharma Inc.$578
  • Galderma Laboratories, L.p.$504
  • Regeneron Healthcare Solutions, Inc.$480
  • Pfizer$358
  • plus $3K from 31 others

What the payments were for

  • Food & beverage$6,24094%
  • Education$3776%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,617 in reported general payments places this provider in the 65th percentile of 222 dermatology providers in Connecticut.

See all dermatology providers in Connecticut

Medicare billing

Part B allowed, 2024
$219,912
Medicare patients
570
Services billed
3,683

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa16$333,902
JubliaEfinaconazole11$13,729
Ketoconazole427$6,165
Halobetasol Propionate76$5,236
Triamcinolone Acetonide360$3,679
Clobetasol Propionate67$2,683
Tretinoin15$1,948
Fluocinonide37$1,237
Doxycycline Hyclate31$1,014
Betamethasone Dipropionate20$1,006
Mupirocin122$866
Imiquimod32$828
Metronidazole23$757
Hydrocortisone83$468
Nystatin11$289

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Ortho Dermatologics, A Division Of Bausch Health US, LLCJublia$302$13,72911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 222 dermatology providers in Connecticut.

Other dermatology in Danbury

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →